CARsgen Therapeutics Holdings Limited
Research CARsgen Therapeutics Holdings Limited (2171.HK) on Bullrun: market cap HKD 6.64B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2171.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 6.64B
- Financial periodFY2025
- RevenueCNY 125.66M
- Revenue growth218.7%
- Net income-CNY 97.86M
- Free cash flow-CNY 243.03M
- Gross margin63.6%
Valuation Snapshot
latest market cap is HKD 6.64B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 125.66M | -CNY 97.86M | -CNY 243.03M | 63.6% | -0.18 | CNY 1.11B | CNY 61.18M | CNY 783.32M |
| FY2024 | CNY 39.43M | -CNY 798.13M | -CNY 429.26M | 37.4% | -1.44 | CNY 1.48B | CNY 166.42M | CNY 1.06B |
| FY2023 | CNY 0 | -CNY 747.79M | -CNY 464.48M | n/a | -1.34 | CNY 1.85B | CNY 85.22M | CNY 1.80B |
| FY2022 | CNY 0 | -CNY 892.25M | -CNY 781.66M | n/a | -1.62 | CNY 2.27B | CNY 119.45M | CNY 2.47B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 6.64B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About CARsgen Therapeutics Holdings Limited
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. The company's products include Zevor-cel (CT053) for the treatment of relapsed/refractory multiple myeloma.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CARsgen Therapeutics Holdings Limited's market cap?
CARsgen Therapeutics Holdings Limited's market capitalization is HKD 6.64B.
What does CARsgen Therapeutics Holdings Limited do?
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. The company's products include Zevor-cel (CT053) for the treatment of relapsed/refractory multiple myeloma.